Mr. Becerra amended the Public Readiness and Emergency Preparedness Act, which was enacted in 2005, to authorize any pharmacist, pharmacy intern or pharmacy technician “who is licensed or certified” to administer orthopoxvirus vaccines and therapeutics, whether it’s “intramuscular, intradermal, or subcutaneous injection, dermal/percutaneous scarification, intranasal or oral administration,” according to an HHS document.
The American Society of Health-System Pharmacists has been advocating for this decision for months, and the ASHP met with the HHS’ Office of the Assistant Secretary for Health Sept. 23 to urge the department to broaden the roles of pharmacists.
“For both vaccines and therapeutics, time is of the essence, and pharmacists and their team are best positioned to quickly ramp up patient services,” Tom Kraus, ASHP’s vice president of government relations, said in a statement.
The American Pharmacists Association also applauded the decision, but because HHS did not mention reimbursement for this added role, interim CEO of APhA, Ilisa Bernstein, PharmD, said in a statement, “We have yet to see what plans are in place to ensure a sustainable model for pharmacists and pharmacies to offer the monkeypox vaccine and treatments.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
